相关产品推荐更多 >

RYBP (人源) IP-WB抗体对 | RYBP (Human) IP-WB Antibody Pair
询价
WDFY3 抗体:偶联FITC|WDFY3 Antibody: FITC
询价
Snaclec rhodocytin subunit alpha Antibody/Snaclec rhodocytin subunit alpha Antibody/Snaclec rhodocytin subunit alpha Antibody
询价
iFluor™ 546 Anti-human CD4 Antibody *HIT4a*/iFluor™ 546 Anti-human CD4 Antibody *HIT4a*/iFluor™ 546 Anti-human CD4 Antibody *HIT4a*
询价
Lipocalin 11 (LCN11) Antibody/Lipocalin 11 (LCN11) Antibody/Lipocalin 11 (LCN11) Antibody
询价
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原:
Homo sapiens / TNF- SF4 receptor I [Homo sapiens]
- 保存条件:
Store at -80℃
- 保质期:
1年
- 级别:
科研级别
- 库存:
100
- 供应商:
艾美捷科技
- 抗体英文名:
Tavolimab (TNF- SF4 receptor I) Antibody, Monoclonal
- 抗体名:
Tavolimab (TNF- SF4 receptor I) Antibody, Monoclonal
- 规格:
0.1mg
Tavolimab (TNF- SF4 receptor I) 抗体, 单克隆,Tavolimab (TNF- SF4 receptor I) Antibody, Monoclonal,Tavolimab (TNF- SF4 receptor I) 抗体, 单克隆,Tavolimab (TNF- SF4 receptor I) Antibody, Monoclonal
产品名称:Tavolimab (TNF- SF4 receptor I) 抗体, 单克隆-Tavolimab (TNF- SF4 receptor I) Antibody, Monoclonal
产品货号:PSI-11-013-0.1mg
产品规格:0.1mg
背景资料:
保存建议:Tavolimab (TNF- SF4 receptor I) 抗体, 单克隆-Tavolimab (TNF- SF4 receptor I) Antibody, MonoclonalStore at -80℃
应用类型:
点击:Tavolimab (TNF- SF4 receptor I) 抗体, 单克隆-Tavolimab (TNF- SF4 receptor I) Antibody, Monoclonal查看更详细产品说明,更多应用、储存、价格、货期等信息请垂询艾美捷科技有限公司。更多ProSci公司特色试剂盒、特色抗体以及特色试剂等产品评论,请点击查看艾美捷特色产品中心。
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验指仅对一种抗原决定基的纯粹的抗体。这类抗体不可能通过将抗原 胞的 Hybridoma,在试管内制成了纯粹的单克隆抗体。用某种抗原使动物产生免疫感应,对应于抗原之不同部分可制成各种不同的抗体复合体。然而,因为一个产生抗体的细胞,只能产生一种抗体,所以骨髓肿瘤细胞与产生抗体细胞间的细胞杂种,可形成边产生抗体边增殖的 hybridoma,将每个杂种细胞进行克隆(无性繁殖系)培养,则一个克隆的细胞群只由单种类产生同一抗体的细胞所组成,这样得到的就是单克隆抗体。此抗体在测定
Tumor necrosis factor-α (TNF-α) is a cytokine (CK) that possesses a wide variety of biological activities, including potent antitumor activities (1 ) and immunomodulatory properties mediated through its binding to two TNF receptors (p55
AntibodyCytokine Fusion Proteins with Members of the TNF-Family
The generation of antibody fusion proteins for target-directed delivery of cytokines constitutes a promising immunotherapeutic approach. The fusion of recombinant antibodies to members of the TNF-family that differ clearly in their soluble
技术资料暂无技术资料 索取技术资料







